Information Provided By: 
Fly News Breaks for April 10, 2015
MDCO
Apr 10, 2015 | 07:09 EDT
After The Medicines Co preannounced lower than expected Q1 revenue, RBC Capital remains upbeat on the company's outlook, citing what it sees as the success of the company's gram negative franchise, its progress on earlier stage, cardiovascular candidates, and approval of and revenue support from up to four products in the near-term. The firm says the shares are "fundamentally inexpensive," while the company has a number of upcoming catalysts. It trimmed its price target on the shares to $37 from $38 but keeps an Outperform rating on the stock.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
